Literature DB >> 709768

Detection of serum cardiac myosin light chains in acute experimental myocardial infarction: radioimmunoassay of cardiac myosin light chains.

B A Khaw, H K Gold, J T Fallon, E Haber.   

Abstract

To develop a more specific plasma test for myocardial infarction, antibodies specific for cardiac myosin light chains (CM-LC) were elicited that showed less than 3% cross-reactivity with skeletal muscle light chains. These antibodies were used to develop a radioimmunoassay for CM-LC that had a sensitivity of 20 ng (+/- 4 SD; P less than 0.001). Normal dog plasma showed no measurable concentrations of CM-LC (n = 6). Plasma samples from 10 dogs with experimental myocardial infarction produced by persistent left anterior descending coronary artery (LAD) occlusion were obtained at 0, 2, 4, 6, 24, 48 and 72 hours. CM-LC were first detectable in all 10 animals 6 hours after occlusion (97.98 +/- 14 ng/ml [mean +/- SEM]; P less than 0.001). Maximal CM-LC levels were usually obtained between 24 and 48 hours. Sham-operated open chest dogs (0--48 hours, n = 3) showed no measurable CM-LC in the plasma samples. Another group of 10 dogs were subjected to 5 hours of LAD occlusion, followed by reperfusion. In four dogs, CM-LC were detectable as early as 1 hour after reperfusion (81.88 +/- 37.75 ng/ml serum). Sera from all 10 dogs showed elevated levels of CM-LC (199.75 +/- 24.0 ng/ml) by 24 hours. Peak CM-LC concentrations were obtained in five dogs at 24 hours (247.0 +/- 35.28 ng/ml) and in another dog at 120 hours (245 ng/ml). Histochemical infarct size was determined to be 0.5--10% of the left ventricular mass at seven days by triphenyltetrazolium chloride staining. The specificity and sensitivity of this radioimmunoassay for detection of CM-LC, unique proteins to the heart, may be valuable in the diagnosis of myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 709768     DOI: 10.1161/01.cir.58.6.1130

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  7 in total

1.  Diagnosis of acute myocardial infarction: CK-MB versus cTn-T in Indian patients.

Authors:  Sanjiv Gupta; K N Singh; V Bapat; V Mishra; D K Agarwal; P Gupta
Journal:  Indian J Clin Biochem       Date:  2008-03-06

Review 2.  Cardiac myofibrillar proteins: biochemical markers to estimate myocardial injury.

Authors:  K H Haider; W H Stimson
Journal:  Mol Cell Biochem       Date:  1999-04       Impact factor: 3.396

3.  Cardiac Myosin Promotes Thrombin Generation and Coagulation In Vitro and In Vivo.

Authors:  Jevgenia Zilberman-Rudenko; Hiroshi Deguchi; Meenal Shukla; Yoshimasa Oyama; Jennifer N Orje; Zihan Guo; Tine Wyseure; Laurent O Mosnier; Owen J T McCarty; Zaverio M Ruggeri; Tobias Eckle; John H Griffin
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-02-27       Impact factor: 8.311

4.  Synthesis and evaluation of an anti-MLC1 × anti-CD90 bispecific antibody for targeting and retaining bone-marrow-derived multipotent stromal cells in infarcted myocardium.

Authors:  C William Gundlach; Amy Caivano; Maria da Graca Cabreira-Hansen; Amir Gahremanpour; Wells S Brown; Yi Zheng; Bradley W McIntyre; James T Willerson; Richard A F Dixon; Emerson C Perin; Darren G Woodside
Journal:  Bioconjug Chem       Date:  2011-08-02       Impact factor: 4.774

5.  Serum myosin light chain determinations in patients with inflammatory myopathy--a preliminary report.

Authors:  R Mader; R Pauzner; E C Keystone; P D Nicol; V J Sehgal; J J Turley
Journal:  Ann Rheum Dis       Date:  1995-07       Impact factor: 19.103

6.  Increase in serum cardiac myosin light chain I associated with elective percutaneous transluminal coronary angioplasty in patients with ischemic heart disease.

Authors:  H Tanaka; K Gotoh; Y Yagi; T Tanaka; K Yamashita; T Suzuki; S Hirakawa
Journal:  Ann Nucl Med       Date:  1992-11       Impact factor: 2.668

7.  Usefulness of myosin in the postmortem diagnosis of myocardial damage.

Authors:  M D Pérez-Cárceles; E Osuna; D N Vieira; A Luna
Journal:  Int J Legal Med       Date:  1995       Impact factor: 2.686

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.